Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJM200506093522322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical treatment of acromegaly - When the tumor size matters: A narrative review.
Growth Horm IGF Res
October 2024
Clinic for Neurosurgery, University Clinical Center of Serbia, Dr Koste Todorovica 4, 11000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.
Medical treatment of acromegaly is generally positioned as a second line of treatment after pituitary adenoma surgery. With the rising availability and variety of medications for acromegaly increases our understanding of their effectiveness and safety. Volume of the published data on the impact of medical therapy on biochemical control of acromegaly, contrasts a relative lack of publications which comprehensively address pituitary tumor alterations under different drug modalities.
View Article and Find Full Text PDFStandards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).
Pituitary
August 2024
Division of Endocrinology, Santiago de Compostela University and Ciber OBN, Santiago, Spain.
Purpose: A series of consensus guidelines on medical treatment of acromegaly have been produced in the last two decades. However, little information is available on their application in clinical practice. Furthermore, international standards of acromegaly care have not been published.
View Article and Find Full Text PDFAcute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly.
JCEM Case Rep
May 2024
Department of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, NSW 2010, Australia.
Article Synopsis
- - A 73-year-old woman with acromegaly developed interstitial nephritis likely caused by oxalate nephropathy, after starting treatment with pasireotide, a medication known to affect pancreatic function and insulin secretion.
- - Despite the treatment improving her IGF-1 levels, the patient experienced gastrointestinal symptoms and acute kidney injury, leading to a kidney biopsy that confirmed acute-on-chronic interstitial nephritis with oxalate crystals present.
- - Following the withdrawal of pasireotide and treatment with glucocorticoids, her kidney function improved significantly over the next few months.
Uncontrolled Acromegaly Resulting in the Need for Left Ventricular Assist Device as Bridge to Heart Transplant.
JCEM Case Rep
May 2024
Department of Endocrinology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Acromegaly is a rare pituitary condition stemming from hypersecretion of growth hormone (GH). Classic presentation involves enlarged hands, feet, and coarse facial features. However, late-onset cardiac manifestations develop in the absence of disease control.
View Article and Find Full Text PDFReal-world value of cabergoline in the treatment of acromegaly.
Best Pract Res Clin Endocrinol Metab
July 2024
Institute of Endocrinology, Rabin Medical Centre, Beilinson Hospital, Petach Tikva, and School of Medicine, Tel-Aviv University, Israel. Electronic address:
Cabergoline is an ergot derivative long-acting dopamine receptor 2 (DR2) selective agonist administered orally and widely used for the treatment of prolactin-secreting adenomas and Parkinson's disease. DR2 is expressed in most somatotroph adenomas. In acromegaly, cabergoline is used off-label and its role is limited by the relatively modest efficacy for achieving hormonal remission and thus, it is largely indicated in patients with mild elevation of GH/IGF-I postoperatively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!